Sunshine Biopharma Inc. (SBFMW)

Every figure below is the company's own, as filed. Nothing is estimated and nothing is smoothed — a period the filing does not support is left blank rather than drawn. Quarters are the company's own, counted from its financial year ending 12-31. Amounts in USD.

Revenue TTM

-15M 0 15M 30M 45M Q4 '17: 0 Q1 '18: 91.2K Q2 '18: 91.2K Q3 '18: 91.2K Q4 '18: 0 Q1 '19: -91K Q2 '19: -87.9K Q3 '19: -80.6K Q4 '19: 21.1K Q1 '20: 32K Q2 '20: 44.1K Q3 '20: 54K Q4 '20: 71.4K Q1 '21: 100.4K Q2 '21: 138.1K Q3 '21: 171.3K Q4 '21: 228.4K Q1 '22: 311K Q2 '22: 408.4K Q3 '22: 490.9K Q4 '22: 4.3M Q1 '23: 9.1M Q2 '23: 14.5M Q3 '23: 20.4M Q4 '23: 24.1M Q1 '24: 26.7M Q2 '24: 30.5M Q3 '24: 33M Q4 '24: 34.9M Q1 '25: 36.2M Q2 '25: 36.3M Q3 '25: 37.3M Q4 '25: 36.3M Q1 '26: 35.5M Q2 '26: 35.3M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Gross Profit TTM

-5M 0 5M 10M 15M Q4 '17: 0 Q1 '18: -9.7K Q2 '18: -9.7K Q3 '18: -9.7K Q4 '18: 0 Q1 '19: 9.7K Q2 '19: 11.3K Q3 '19: 13.4K Q4 '19: 10.1K Q1 '20: 17.2K Q2 '20: 25.6K Q3 '20: 34.4K Q4 '20: 45.6K Q1 '21: 59.9K Q2 '21: 84.3K Q3 '21: 104.3K Q4 '21: 110.6K Q1 '22: 151.9K Q2 '22: 193.1K Q3 '22: 229.3K Q4 '22: 1.7M Q1 '23: 3.5M Q2 '23: 5.3M Q3 '23: 7.3M Q4 '23: 8.3M Q1 '24: 8.9M Q2 '24: 9.3M Q3 '24: 10.1M Q4 '24: 10.7M Q1 '25: 11M Q2 '25: 12.1M Q3 '25: 12.3M Q4 '25: 12.3M Q1 '26: 11.7M Q2 '26: 10.7M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '16: -831.3K Q4 '16: -993.1K Q1 '17: -1M Q2 '17: -1M Q3 '17: -1M Q4 '17: -857.2K Q1 '18: -914.9K Q2 '18: -1M Q3 '18: -1.2M Q4 '18: -1.2M Q1 '19: -1.1M Q2 '19: -620.9K Q3 '19: -534.8K Q4 '19: -641.6K Q1 '20: -557.1K Q2 '20: -619.5K Q3 '20: -484.1K Q4 '20: -576.9K Q1 '21: -1.8M Q2 '21: -2.1M Q3 '21: -2.5M Q4 '21: -2.4M Q1 '22: -2.4M Q2 '22: -2.7M Q3 '22: -3.9M Q4 '22: -27M Q1 '23: -27.6M Q2 '23: -27.9M Q3 '23: -27M Q4 '23: -4.8M Q1 '24: -4.3M Q2 '24: -4.6M Q3 '24: -4.9M Q4 '24: -5.8M Q1 '25: -5.7M Q2 '25: -6.5M Q3 '25: -6.5M Q4 '25: -6.2M Q1 '26: -6.3M Q2 '26: -5.9M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Net Income TTM

-30M -20M -10M 0 10M 20M 30M Q3 '16: -3M Q4 '16: -3.5M Q1 '17: -3.4M Q2 '17: -3.4M Q3 '17: -2M Q4 '17: -1M Q1 '18: -1.1M Q2 '18: -1.3M Q3 '18: -2M Q4 '18: -2.2M Q1 '19: -2.1M Q2 '19: -2.2M Q3 '19: -1.6M Q4 '19: -1.7M Q1 '20: -1.6M Q2 '20: -1.7M Q3 '20: -2.1M Q4 '20: -2.8M Q1 '21: -8.9M Q2 '21: -10.8M Q3 '21: -14.2M Q4 '21: -12.5M Q1 '22: -7.5M Q2 '22: -5.2M Q3 '22: -2.6M Q4 '22: -26.7M Q1 '23: -27.2M Q2 '23: -27.6M Q3 '23: -26.8M Q4 '23: -4.5M Q1 '24: -4.1M Q2 '24: -3.7M Q3 '24: -4.2M Q4 '24: -5.1M Q1 '25: -5M Q2 '25: -6.3M Q3 '25: -6M Q4 '25: -6M Q1 '26: -6M Q2 '26: -5.8M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Cost of Revenue TTM

-9M 0 9M 18M 27M Q4 '17: 0 Q1 '18: 100.8K Q2 '18: 100.8K Q3 '18: 100.8K Q4 '18: 0 Q1 '19: -100.7K Q2 '19: -99.2K Q3 '19: -94K Q4 '19: 11.1K Q1 '20: 14.8K Q2 '20: 18.5K Q3 '20: 19.6K Q4 '20: 25.8K Q1 '21: 40.5K Q2 '21: 53.8K Q3 '21: 67K Q4 '21: 117.8K Q1 '22: 159.2K Q2 '22: 215.3K Q3 '22: 261.6K Q4 '22: 2.6M Q1 '23: 5.7M Q2 '23: 9.2M Q3 '23: 13.1M Q4 '23: 15.8M Q1 '24: 17.9M Q2 '24: 21.2M Q3 '24: 22.8M Q4 '24: 24.2M Q1 '25: 25.2M Q2 '25: 24.2M Q3 '25: 25M Q4 '25: 24.1M Q1 '26: 23.8M Q2 '26: 24.6M Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Operating Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q3 '16: -625.8K Q4 '16: -314.2K Q1 '17: -340.6K Q2 '17: -280K Q3 '17: -365.2K Q4 '17: -543.5K Q1 '18: -603.9K Q2 '18: -583.6K Q3 '18: -606.2K Q4 '18: -512.8K Q1 '19: -578.3K Q2 '19: -568.3K Q3 '19: -484K Q4 '19: -495.8K Q1 '20: -292.9K Q2 '20: -327.4K Q3 '20: -361.5K Q4 '20: -657.3K Q1 '21: -923.6K Q2 '21: -1.5M Q3 '21: -1.9M Q4 '21: -1.8M Q1 '22: -2.8M Q2 '22: -2.8M Q3 '22: -3.3M Q4 '22: -5.2M Q1 '23: -5.8M Q2 '23: -9M Q3 '23: -8.3M Q4 '23: -8.8M Q1 '24: -10.1M Q2 '24: -10.9M Q3 '24: -11.8M Q4 '24: -12.5M Q1 '25: -11M Q2 '25: -7.7M Q3 '25: -7.1M Q4 '25: -5.3M Q1 '26: -5.7M Q2 '26: -5.4M Q3 '17 Q4 '18 Q1 '20 Q2 '21 Q3 '22 Q4 '23 Q1 '25 Q2 '26

Free Cash Flow TTM

-15M -10M -5M 0 5M 10M 15M Q4 '16: -317.6K Q1 '17: -344.1K Q2 '17: -303.4K Q3 '17: -366.3K Q4 '17: -547.2K Q1 '18: -612.4K Q2 '18: -587.3K Q3 '18: -637.3K Q4 '19: -496.7K Q4 '24: -14.2M Q1 '25: -12.6M Q2 '25: -8.5M Q3 '25: -7.4M Q4 '25: -5.5M Q1 '26: -5.9M Q2 '26: -5.4M Q1 '17 Q3 '17 Q1 '18 Q3 '18 Q4 '24 Q2 '25 Q4 '25 Q2 '26

Operating cash flow minus capital expenditure.

Shares Outstanding Quarterly

0 350M 700M 1.1B Q2 '13: 56.6M Q3 '13: 56.9M Q1 '14: 61.1M Q2 '14: 65.5M Q3 '14: 67.8M Q1 '15: 64.7M Q2 '15: 119.9M Q3 '15: 130.1M Q1 '16: 215.6M Q2 '16: 262.4M Q3 '16: 262.4M Q1 '17: 805.6M Q2 '17: 857.5M Q3 '17: 907.7M Q1 '18: 47.1M Q2 '18: 50M Q3 '18: 50M Q1 '19: 4.3M Q2 '19: 5M Q3 '19: 8.3M Q1 '20: 37.6M Q2 '20: 153.1M Q3 '20: 280.9M Q1 '21: 2.2M Q2 '21: 2.4M Q3 '21: 2.5M Q1 '22: 5.3M Q2 '22: 15.8M Q3 '22: 18.9M Q1 '23: 220.4K Q2 '23: 12.7K Q3 '23: 12.8K Q1 '24: 641.3K Q2 '24: 40.9K Q3 '24: 1.3M Q1 '25: 2.7M Q2 '25: 3.6M Q3 '25: 4.6M Q1 '26: 4.9M Q2 '26: 1.4M Q3 '14 Q2 '16 Q1 '18 Q3 '19 Q2 '21 Q1 '23 Q3 '24 Q2 '26

Weighted average diluted, as the filer reports it for each period. An average cannot be added across periods, so this one is always shown per period the filer tagged rather than as a trailing year.

EPS TTM

-240.00 -160.00 -80.00 0.00 80.00 160.00 240.00 Q1 '15: -0.02 Q2 '15: -0.01 Q3 '15: -0.01 Q4 '15: 0.00 Q1 '16: 0.00 Q2 '16: 0.00 Q3 '16: -0.01 Q4 '16: -0.01 Q1 '17: -0.01 Q2 '17: -0.01 Q3 '17: 0.00 Q4 '17: -0.02 Q1 '18: -0.02 Q2 '18: -0.03 Q3 '18: -0.05 Q4 '18: -0.70 Q1 '19: -0.75 Q2 '19: -0.88 Q3 '19: -0.90 Q4 '19: -0.15 Q1 '20: -0.10 Q2 '20: 0.03 Q3 '20: 0.07 Q4 '20: -2.73 Q1 '21: -5.55 Q2 '21: -6.75 Q3 '21: -8.34 Q4 '21: -4.76 Q1 '22: -2.17 Q2 '22: -0.99 Q3 '22: 0.68 Q4 '22: -2.20 Q1 '23: -9.70 Q2 '23: -80.84 Q3 '23: -131.64 Q4 '23: -215.27 Q1 '24: -209.54 Q4 '25: -1.44 Q1 '26: -1.25 Q2 '26: -1.58 Q1 '16 Q2 '17 Q3 '18 Q4 '19 Q1 '21 Q2 '22 Q3 '23 Q2 '26

The filer's own published earnings a share for each quarter, four quarters added up. The company page divides trailing net income by the share count instead, which lands within about 1% of this and is not the same sum, so the two are named differently rather than presented as one figure.